These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30740737)

  • 1. Proposal for an individualized dietary strategy in patients with very long-chain acyl-CoA dehydrogenase deficiency.
    Bleeker JC; Kok IL; Ferdinandusse S; de Vries M; Derks TGJ; Mulder MF; Williams M; Gozalbo ER; Bosch AM; van den Hurk DT; de Sain-van der Velden MGM; Waterham HR; Wijburg FA; Visser G
    J Inherit Metab Dis; 2019 Jan; 42(1):159-168. PubMed ID: 30740737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fatty acid oxidation flux predicts the clinical severity of VLCAD deficiency.
    Diekman EF; Ferdinandusse S; van der Pol L; Waterham HR; Ruiter JP; Ijlst L; Wanders RJ; Houten SM; Wijburg FA; Blank AC; Asselbergs FW; Houtkooper RH; Visser G
    Genet Med; 2015 Dec; 17(12):989-94. PubMed ID: 25834949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of newborn screening for very-long-chain acyl-CoA dehydrogenase deficiency on genetic, enzymatic, and clinical outcomes.
    Bleeker JC; Kok IL; Ferdinandusse S; van der Pol WL; Cuppen I; Bosch AM; Langeveld M; Derks TGJ; Williams M; de Vries M; Mulder MF; Gozalbo ER; de Sain-van der Velden MGM; Rennings AJ; Schielen PJCI; Dekkers E; Houtkooper RH; Waterham HR; Pras-Raves ML; Wanders RJA; van Hasselt PM; Schoenmakers M; Wijburg FA; Visser G
    J Inherit Metab Dis; 2019 May; 42(3):414-423. PubMed ID: 30761551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue-specific strategies of the very-long chain acyl-CoA dehydrogenase-deficient (VLCAD-/-) mouse to compensate a defective fatty acid β-oxidation.
    Tucci S; Herebian D; Sturm M; Seibt A; Spiekerkoetter U
    PLoS One; 2012; 7(9):e45429. PubMed ID: 23024820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De novo fatty acid biosynthesis and elongation in very long-chain acyl-CoA dehydrogenase-deficient mice supplemented with odd or even medium-chain fatty acids.
    Tucci S; Behringer S; Spiekerkoetter U
    FEBS J; 2015 Nov; 282(21):4242-53. PubMed ID: 26284828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infants suspected to have very-long chain acyl-CoA dehydrogenase deficiency from newborn screening.
    Merritt JL; Vedal S; Abdenur JE; Au SM; Barshop BA; Feuchtbaum L; Harding CO; Hermerath C; Lorey F; Sesser DE; Thompson JD; Yu A
    Mol Genet Metab; 2014 Apr; 111(4):484-92. PubMed ID: 24503138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and cellular pathology of very-long-chain acyl-CoA dehydrogenase deficiency.
    Schiff M; Mohsen AW; Karunanidhi A; McCracken E; Yeasted R; Vockley J
    Mol Genet Metab; 2013 May; 109(1):21-7. PubMed ID: 23480858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follow-up of fatty acid β-oxidation disorders in expanded newborn screening era.
    Janeiro P; Jotta R; Ramos R; Florindo C; Ventura FV; Vilarinho L; Tavares de Almeida I; Gaspar A
    Eur J Pediatr; 2019 Mar; 178(3):387-394. PubMed ID: 30617651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The fate of medium-chain fatty acids in very long-chain acyl‑CoA dehydrogenase deficiency (VLCADD): A matter of sex?
    Wehbe Z; Alatibi K; Jellusova J; Spiekerkoetter U; Tucci S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Nov; 1864(11):1591-1605. PubMed ID: 31394165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of bezafibrate for preventing myopathic attacks in patients with very long-chain acyl-CoA dehydrogenase deficiency.
    Shiraishi H; Yamada K; Egawa K; Ishige M; Ochi F; Watanabe A; Kawakami S; Kuzume K; Watanabe K; Sameshima K; Nakamagoe K; Tamaoka A; Asahina N; Yokoshiki S; Kobayashi K; Miyakoshi T; Oba K; Isoe T; Hayashi H; Yamaguchi S; Sato N
    Brain Dev; 2021 Feb; 43(2):214-219. PubMed ID: 32798077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety of Lipistart, a medium-chain triglyceride based formula, in the dietary treatment of long-chain fatty acid disorders: a phase I study.
    MacDonald A; Webster R; Whitlock M; Gerrard A; Daly A; Preece MA; Evans S; Ashmore C; Chakrapani A; Vijay S; Santra S
    J Pediatr Endocrinol Metab; 2018 Mar; 31(3):297-304. PubMed ID: 29425111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac tissue citric acid cycle intermediates in exercised very long-chain acyl-CoA dehydrogenase-deficient mice fed triheptanoin or medium-chain triglyceride.
    Gaston G; Gangoiti JA; Winn S; Chan B; Barshop BA; Harding CO; Gillingham MB
    J Inherit Metab Dis; 2020 Nov; 43(6):1232-1242. PubMed ID: 33448436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management and diagnosis of mitochondrial fatty acid oxidation disorders: focus on very-long-chain acyl-CoA dehydrogenase deficiency.
    Yamada K; Taketani T
    J Hum Genet; 2019 Feb; 64(2):73-85. PubMed ID: 30401918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of newborn screening for fatty acid oxidation disorders on neurological outcome: A Belgian retrospective and multicentric study.
    Everard E; Laeremans H; Boemer F; Marie S; Vincent MF; Dewulf JP; Debray FG; De Laet C; Nassogne MC
    Eur J Paediatr Neurol; 2024 Mar; 49():60-65. PubMed ID: 38377647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic challenge in very-long chain acyl-CoA dehydrogenase deficiency (VLCADD).
    Hesse J; Braun C; Behringer S; Matysiak U; Spiekerkoetter U; Tucci S
    J Inherit Metab Dis; 2018 Nov; 41(6):1169-1178. PubMed ID: 30194637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent ACADVL molecular findings in individuals with a positive newborn screen for very long chain acyl-coA dehydrogenase (VLCAD) deficiency in the United States.
    Miller MJ; Burrage LC; Gibson JB; Strenk ME; Lose EJ; Bick DP; Elsea SH; Sutton VR; Sun Q; Graham BH; Craigen WJ; Zhang VW; Wong LJ
    Mol Genet Metab; 2015 Nov; 116(3):139-45. PubMed ID: 26385305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Very long-chain acyl-coenzyme A dehydrogenase deficiency in Chinese patients: eight case reports, including one case of prenatal diagnosis.
    Li X; Ding Y; Ma Y; Liu Y; Wang Q; Song J; Yang Y
    Eur J Med Genet; 2015 Mar; 58(3):134-9. PubMed ID: 25652019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial.
    Ørngreen MC; Madsen KL; Preisler N; Andersen G; Vissing J; Laforêt P
    Neurology; 2014 Feb; 82(7):607-13. PubMed ID: 24453079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disrupted fat distribution and composition due to medium-chain triglycerides in mice with a β-oxidation defect.
    Tucci S; Flögel U; Sturm M; Borsch E; Spiekerkoetter U
    Am J Clin Nutr; 2011 Aug; 94(2):439-49. PubMed ID: 21697078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatty liver in a two days old neonate.
    Arivalagan P; Husain MS; Subramaniam K; Kaslan MRM
    Med J Malaysia; 2019 Oct; 74(5):454-455. PubMed ID: 31649231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.